抗炎症治療薬と市場：標的・技術・市場・戦略・予測

先進国の平均寿命が延び、人口が高齢化するにつれて、慢性疼痛および急性疼痛の発生率と関連する罹患率が増加し、患者とその家族にとってQOLの問題である疼痛管理がより重要視されるようになってきています。

当レポートでは、抗炎症治療薬の市場を調査し、炎症性疾患の概要、治療標的、法規制環境、市場影響因子の分析、市場規模の推移・予測、市場シェア、参入企業のプロファイルなどをまとめています。

目次

エグゼクティブサマリー

炎症経路

炎症経路標的カスケード

サイトカイン

• インターロイキン6（IL-6）
• インターロイキンIL-6R
• インターロイキン-21（IL-21）
• インターロイキン-21R（IL-21R）
• インターロイキン-23（IL-23）
• インターロイキン-23R（IL-23R）
• インターロイキン-17A（IL-17A）
• インターロイキン-17C（IL-17C）
• インターロイキン17A/17F
• インターロイキン-17RA（IL-17RA）
• インターロイキン17
• インターロイキン-22（IL-22）

ヤヌスキナーゼ/チロシンキナーゼ阻害剤

シグナル伝達タンパク質

• 転写のシグナルトランスデューサー&アクティベーター

形質転換成長因子-βRI/RII（TGF-βRI/RII）

レチノイン酸関連オーファン受容体RORyt

市場の状況

市場規模

競合情勢

免疫メディエーター市場の評価

• 対応可能市場
• 競合情勢

市場参入企業のプロファイル

Mediating the Inflammatory Cascade

The influence of immune mediators on inflammatory diseases has put the immune mediated therapeutics at the center of inflammatory disease treatment and management. The result is a growing list of approved and development-stage drugs designed to inhibit at least one of the fifteen pathway targets that drive the transcription and secretion of inflammatory cytokines into the extracellular space where they impact patient morbidity and inflammatory disease burden. The competitive landscape now includes more than two dozen drug developers. As this marketspace has evolved, the prime product opportunities, which we define as the drugability of individual pathway targets factored by the inverse of the number of competing drugs and late-stage candidates, has been shrinking. The distribution of therapeutic products in this segment varies across pathway elements, with 84 percent targeting signaling proteins and ligands, and receptors and transcription factors accounting for 8 percent each.

Targeting Key Inflammatory Pathways:

The identification of key immune mechanisms as causative for human inflammatory disease has led to the approval and rapid development of novel therapeutic agents.

Monoclonal antibodies to a variety of cytokines and cytokine receptors and small-molecule inhibitors of RORyt and JAKs are changing the therapeutic landscape, with three dozen distinct products now approved or in clinical development.

Humanized monoclonal antibodies to both IL-17 and IL-17RA are enabling improved outcomes for moderate to severe psoriasis as well as psoriatic arthritis.

What You Will Learn:

• What are the immune factors that are responsible for immune mediated inflammatory Diseases?

• What are the inflammatory-mediated ligands, receptors, signaling proteins and transcription factors that represent druggable targets?

• What are the major factors driving the high level of development activity in immune mediated inflammatory diseases?

• What is the size of the market today, who are the market share leaders?

• What will be the effects of competing pathway solutions for the same indication and how will this dynamic impact revenue forecasts over the next four years?

• What are the significant economic, technology, and regulatory factors affecting the market for immune therapeutics?

Table of Contents

Executive Summary

Inflammatory Pathways

Inflammatory Pathway Cascade Targets

Cytokines

• Interleukin 6 (IL-6)
• Interleukin IL-6R

• Interleukin-21 (IL-21)
• Interleukin-21R (IL-21R)
• Interleukin-23 (IL-23)

• Interleukin-23R (IL-23R)
• Interleukin-17A (IL-17A)
• Interleukin-17C (IL-17C)

• Interleukin 17A/17F
• Interleukin-17RA (IL-17RA)
• Interleukin 17
• Interleukin-22 (IL-22)

Janus Kinase/Tyrosine Kinase Inhibitors

Signaling Proteins

• Signal Transducer & Activator of Transcription

Transforming Growth Factor-β RI/RII (TGF-β RI/RII)

Retinoic acid-related orphan receptor RORyt

Market Status

Market Size

Competitive Landscape

Immune Mediated Market Assessment

• Addressable Market
• Competitive Landscape

Profiles of Market Participants